(512) 886-8286
Contact Us
invest@monogramorthopedics.com
Hours of operation:  8 AM - 6 PM EST
415-903-6859

Final Day to Invest

Days
Hours
Minutes
Seconds
ROUND OVERSUBSCRIBED
$5,000,000+
Investors will be allocated shares on a first-to-fund basis. Not all subscriptions have been funded so there is still the opportunity to invest. Fund your investment immediately to secure your place in this round!

Surgery Will Never be the Same

Our precision robotic surgical assistants and FDA-approved, personalized knee implants are changing the way surgery is done forever. With over 14 patents in progress, our innovations are protected from imitators. Read on to learn how you stand to benefit as an investor.

Min. Investment

$500

Share Price

$10.01

Valuation

$155,000,000
INVEST NOW
PLAY VIDEO
form cOFFERING circular

Min. Investment

$500

Share Price

$10.01

Valuation

$155,000,000

NASDAQ Here We Come. Meet MGRM.

We’ve reserved the Monogram stock ticker - MGRM - a key step in our journey to going public*. In the meantime, our current private round remains open.

What People are Saying

"Given the sheer number of knee and hip replacement procedures every year, the fact that joint reconstruction technology has remained unchanged for over 50 years is perplexing."

"Monogram has a first-to-market advantage in a sector that's about to get even more competitive."

"Monogram Orthopedics is ushering in personalized orthopedic care by combining proprietary 3D printing technology with next-generation navigated surgical robotics".

"Monogram is developing a better way by commercializing highly personalized joint implants unique to every patient and a first-of-its-kind active robotics system that performs precise bone cuts."

"Monogram has conducted studies with UCLA and demonstrated Monogram process was about seven times more stable than current hip replacement techniques."

National Science Foundation

A Broken Industry

Joint replacement technology is mostly the same today as it was 40 years ago. Surgeons use crude instruments like hand saws and jigs to prepare the bone for rigid, generic implants. No wonder the results are so bad. 

  1. Over 100,000 knee replacements fail each year
  2. Up to ⅓ of patients have chronic pain after an implant surgery
  3. Instability, malalignment, and failure of fixation cause 50% of early revision surgeries
INVEST NOW

Robots in the Operating Room

Surgery is an incredibly invasive stressful process. Our surgical robots precisely create a digital map of a patient and make as minimal incisions as possible alongside surgeons to create a better surgery experience.

In fact, this year we held a live demonstration where a Monogram robot successfully operated on a cadaver alongside a surgeon in front of a virtual audience of over 5,000 people.

What makes the Monogram robot so effective?

  1. 7 degrees of freedom to boost range of motion
  2. Closed loop tracking
  3. Active navigated milling gently clears space for the implant

The World Deserves Personalized Implants

You wouldn’t wear a one size fits all shoe, so why would you accept a one size fits all knee replacement? You wouldn’t, but people have accepted this as the standard for years. 

We aim to change this. Our implants are patient optimized and designed to meet individual patient’s anatomy as closely as possible. The result is a decrease in micro mobility which increases likelihood of acceptance of the implant by a patient.

    The Knee Replacement Market is $19.6B

    By 2027, 50% of all knee replacements will be robotic. We aim to have the first active navigated robotic arm on the market. If we are able to succeed we will capture a fraction of this massive market

    Company Highlights

    Generated Revenue

    Implant sales in 2021 with 2 active distributors

    NSF Grant

    Winner of prestigious award from National Science Foundation (NSF)

    Cadaver Lab

    350 sq. ft. cadaver lab complete

    14 Patents

    14 Patent applications filed

    $26M

    Have already raised $26M
    INVEST NOW

    Meet the Team

    See Our Team
    Executive Leadership Team
    Engineering Leadership Team
    Scientific Advisory Board
    Orthopedic Surgeon Panel

    Douglas Unis, Md

    Founder & Chief Medical Officer

    Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.

    Benjamin Sexson - CEO

    CFA, Chief Executive Officer

    Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.

    Paul Riss

    CPA, MBA, INTERIM CFO

    Experienced executive with a demonstrated history of completing SEC filings, focusing on the Securities Exchange Act of 1934 and Section 4(a)(6) of the Securities Act of 1933.  Currently serves as a Director for NetCapital and was a CPA with Ernst & Young.

    Kamran Shamaei, PhD

    CTO

    Kamran Shamaei received a Ph.D. from Yale University and MSc from ETH Zurich and did his postdoctoral research at Stanford University, focusing on Medical Robotics. He has extensive experience developing FDA cleared surgical robots.

    Christopher Scifert, PhD

    Director of Product Development Implants and Instruments

    Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

    Kevin Posey

    DIRECTOR OF QUALITY AND REGULATORY ASSURANCE

    Muhammad Afnan

    Director of Software Engineering

    Sophia Sangiorgio, PhD

    Director, Orthopaedic Institute for Children

    Laura Gilmour

    Global Medical B. Development Manager at EOS NA

    Matt DiCicco, M.S.

    Robotics, MIT

    Dr. Roshan Shah

    Director of Complex Adult Hip and Knee Reconstruction at Columbia University

    Robert Jamieson

    Board Certified Orthopaedic Surgeon at The Orthopedic Specialty Center of Northern California

    Dr. Matthew E. Heinrich

    Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

    Darwin Chen

    Associate Professor of Orthopaedics at Icahn School of Medicine at Mt Sinai

    Dr. Gregory Catlett

    Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

    FAQs

     Why invest in startups?
    Crowdfunding allows investors to support startups and early-growth companies that they are passionate about. This is different from helping a company raise money on Kickstarter. With Regulation CF Offerings, you aren’t buying products or merchandise. You are buying a piece of a company and helping it grow.
    How much can I invest?
    Investors other than accredited investors are limited in the amounts they are allowed to invest in all Regulation Crowdfunding offerings (on this site and elsewhere) over the course of a 12-month period: If either of an investor’s annual income or net worth is less than $107,000, then the investor’s investment limit is $2,200, or 5 percent of the greater of the investor’s annual income or net worth, whichever is greater. If both an investor’s annual income and net worth are $107,000 or higher, then the investor’s limit is 10 percent of the greater of their annual income or net worth, or $107,000 whichever is greater. Accredited investors are not limited in the amount they can invest.
    How do I calculate my net worth?
    Calculating net worth involves adding up all your assets and subtracting all your liabilities (excluding the value of the person’s primary residence). The resulting sum is your net worth.
    What are the tax implications of an equity crowdfunding investment?
    We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
    What are the tax implications of an equity crowdfunding investment?
    We cannot give tax advice, and we encourage you to talk with your accountant or tax advisor before making an investment.
    Who can invest in a Regulation CF Offering?
    Individuals over 18 years of age can invest.
    What do I need to know about early-stage investing? Are these investments risky?
    Investing in startups and small businesses is inherently risky and standard company risk factors such as execution and strategy risk are often magnified at the early stages of a company. In the event that a company goes out of business, your ownership interest could lose all value. Furthermore, private investments in startup companies are illiquid instruments that typically take up to five and seven years (if ever) before an exit via acquisition, IPO, etc.
    When will I get my investment back?
    Monogram Orthopaedics Inc.. is a privately held company, and its shares are not traded on a public stock exchange. As a result, the shares cannot be easily traded or sold. As an investor in a private company, you typically receive a return on your investment under the following two scenarios: The company gets acquired by another company. The company goes public (makes an initial public offering on the NASDAQ, NYSE, or another exchange). In those instances, you receive your pro-rata share of the distributions that occur, in the case of acquisition, or you can sell your shares on the exchange. It can take 5-7 years (or longer) to see a distribution or trading, as it takes years to build companies. In many cases, there will not be any return as a result of business failure. Investments in private placements and start-up investments in particular are speculative and involve a high degree of risk, and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investments tend to be in earlier stages of development, and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors on Regulation CF offerings will receive securities that are subject to holding period requirements. The most sensible investment strategy for start-up investing may include a balanced portfolio of different start-ups. Start-ups should only be part of your overall investment portfolio. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest.
    Can I sell my shares?
    Shares sold via Regulation Crowdfunding offerings have a one-year lock up period before those shares can be sold under certain conditions.
    Exceptions to limitations on selling shares during the one-year lock up are transfers:
    - to the company that issued the securities; - to an accredited investor; - to a family member (defined as a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships.); - in connection with your death or divorce or other similar circumstance;
    What happens if a company does not reach their funding goal?
    If a company does not reach their minimum funding goal, all funds will be returned to the investors after the closing of their offering.
    How can I learn more about a company's offering?
    All available financial information can be found on the offering pages for the company’s Regulation Crowdfunding offering.
    What if I change my mind about investing?
    You may cancel your investment at any time, for any reason until 48 hours prior to a closing occurring. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To submit a request to cancel your investment please email info@monogramorthopedics.com.

    Join the Discussion

    Loading Comments

    Keep in Touch

    Join our mailing list to receive live investor updates!

    Thank you! Your submission has been received!
    Oops! Something went wrong while submitting the form.